Molly Braun, PhD

Senior Scientist
Vaxart, Inc
South San Francisco, California, United States

Disclosure(s): Vaxart, Inc: Stocks/Bonds (Public Company), TREATMENT OF LONG COVID WITH ORALLY AND MUCOSALLY ADMINISTERED ADENOVIRAL VECTORS

Presentation(s):

• 594 - A Phase I, Multicenter, Randomized, Double-blind, Placebo-controlled Single Dose, Dose-ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of Orally Administered Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females ≥ 18 years Old and Their Breast-feeding Infants

  Saturday, October 19, 2024
  2:15 PM – 2:30 PM US PT